Disease Overview：Primary hypertension（PH）
Primary hypertension, also known as essential hypertension, is a chronic cardiovascular condition characterized by persistently elevated systemic arterial blood pressure—typically defined as systolic pressure ≥140 mmHg and/or diastolic pressure ≥90 mmHg on repeated measurements—without an identifiable secondary cause. It affects over one billion people globally and is a leading modifiable risk factor for stroke, myocardial infarction, heart failure, chronic kidney disease, and vascular dementia. Pathophysiologically, it involves complex interactions among genetic predisposition, sympathetic nervous system overactivity, renin-angiotensin-aldosterone system dysregulation, endothelial dysfunction, and environmental contributors such as sodium excess, obesity, physical inactivity, and psychosocial stress. Diagnosis requires careful clinical evaluation, ambulatory or home blood pressure monitoring, and exclusion of secondary etiologies via targeted laboratory testing and imaging. Management emphasizes individualized, guideline-concordant pharmacotherapy—including ACE inhibitors, ARBs, calcium channel blockers, thiazide-like diuretics, and beta-blockers—as well as sustained lifestyle modification.
China offers distinct advantages for international patients seeking hypertension management: its tier-3 hospitals house nationally certified hypertension specialists with extensive experience in complex, treatment-resistant cases; advanced non-invasive diagnostic tools—including 24-hour ambulatory BP monitoring, central aortic pressure assessment, and cardiac MRI for target organ damage evaluation—are widely available; real-world outcome data demonstrate high rates of BP control and cardiovascular event reduction in standardized care pathways; and comprehensive treatment packages—including initial workup, medication titration, lifestyle counseling, and long-term follow-up—are typically 40–60% more cost-effective than comparable services in the US, UK, or Germany. As a dedicated medical tourism agency, we facilitate seamless access to China’s top cardiovascular centers by coordinating hospital appointments, verifying physician credentials, providing itemized, transparent pricing in advance, arranging medical visas and local logistics, and offering bilingual clinical support throughout the patient journey—from pre-travel consultation to post-discharge telehealth follow-up.
Primary hypertension: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Essential Hypertension (Primary Hypertension) — Cardiovascular Department
Non-Surgical / Conservative Management
*Target criteria:* BP ≥140/90 mmHg (confirmed on ≥2 separate visits); Stage 1–2 hypertension without end-organ damage or refractory symptoms.
- •Initial Lifestyle Intervention (3–6 months)
- 12-session supervised aerobic/resistance training program: $180–$260 - Smoking cessation pharmacotherapy + behavioral support (varenicline/bupropion): $120–$190
- •First-Line Pharmacotherapy (Monthly, per drug class)
- Calcium channel blocker (e.g., amlodipine 5 mg): $5–$9 - Thiazide diuretic (e.g., chlorthalidone 12.5 mg): $3–$6 - Beta-blocker (e.g., bisoprolol 5 mg): $6–$10
- •Monitoring & Diagnostic Fees (Per Visit/Annual)
- ECG + echocardiogram (LV mass index assessment): $130–$185 - Renal function panel (creatinine, eGFR, urinalysis): $25–$40 - Serum electrolytes + fasting glucose + lipid profile: $35–$55
Interventional / Procedural Options
*Eligibility:* Resistant hypertension (≥3 drugs including diuretic, BP >140/90 mmHg), confirmed adherence, exclusion of secondary causes, no significant renal artery stenosis or severe LV dysfunction.
- •Renal Denervation (RDN)
- Procedure (bilateral endovascular RDN with Symplicity Spyral or similar CE-marked device): $4,800–$6,300 - Post-procedure follow-up (3-month BP reassessment + repeat ABPM): $190–$270
Special/Complex Condition Management
- •Hypertensive Emergency (BP ≥180/120 mmHg + acute target-organ injury)
- Urgent brain MRI + cardiac biomarkers + urgent renal ultrasound: $1,100–$1,520
- •Hypertension with Chronic Kidney Disease (eGFR <60 mL/min/1.73m²)
- Annual urine albumin-to-creatinine ratio (UACR) + renal Doppler: $65–$95
Quick Selection Guide
- •<45 years, Stage 1, no comorbidities: Start with lifestyle intervention + single low-dose CCB or ACEi ($250–$400/year total)
- •55–75 years, Stage 2 + diabetes: Dual therapy (CCB + ACEi) + annual echocardiogram + UACR ($420–$680/year)
- •Resistant hypertension, failed ≥4 drugs: Renal denervation after full pre-op workup ($6,100–$8,400 one-time)
- •Acute hypertensive encephalopathy or pulmonary edema: Immediate ICU-based management ($1,800–$2,500 first 72 hrs)
- •Budget-constrained (<$300/year): Generic thiazide + home BP monitor ($40) + free community health center follow-up ($110–$190/year)
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Primary hypertension Medical Vacation Packages
Curated transparent all-inclusive packages combining Primary hypertension treatment with China top medical destinations:
